Sydney E. Salmon
#169,307
Most Influential Person Now
Sydney E. Salmon's AcademicInfluence.com Rankings
Sydney E. Salmonmedical Degrees
Medical
#3515
World Rank
#3986
Historical Rank
Hematology
#51
World Rank
#57
Historical Rank
Download Badge
Medical
Why Is Sydney E. Salmon Influential?
(Suggest an Edit or Addition)Sydney E. Salmon's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival (1975) (2956)
- Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. (1997) (563)
- Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. (1989) (561)
- Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. (2006) (494)
- RAISED SERUM LEVELS OF TUMOUR NECROSIS FACTOR IN PARASITIC INFECTIONS (1986) (472)
- P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. (1991) (393)
- Dose response evaluation of adriamycin in human neoplasia (1977) (362)
- B-cell neoplasia in man. (1974) (252)
- Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. (1980) (234)
- Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. (2002) (231)
- Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. (1991) (229)
- Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. (1989) (218)
- Kinetics of tumor growth and regression in IgG multiple myeloma. (1972) (208)
- Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer (1975) (190)
- Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. (1991) (185)
- Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. (1994) (143)
- High speed scintillation autoradiography (1975) (140)
- Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. (1983) (140)
- Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. (1989) (136)
- P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. (1993) (127)
- Immunohistochemical detection and quantitation of p-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation (1989) (122)
- Relation of Osteoclast Activating Factor Production to Extent of Bone Disease in Multiple Myeloma (1981) (115)
- Polyamines as predictors of success and failure in cancer chemotherapy (1975) (101)
- P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy (1993) (99)
- Expansion of the growth fraction in multiple myeloma with alkylating agents. (1975) (94)
- Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. (1991) (92)
- Amyloid production in human myeloma stem-cell culture, with morphologic evidence of amyloid secretion by associated macrophages. (1982) (87)
- Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study. (1986) (83)
- Human myeloma in vitro colony growth: interrelationships between drug sensitivity, cell kinetics, and patient survival duration. (1983) (80)
- cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. (2001) (76)
- High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. (1999) (74)
- Immunoglobulin synthesis and tumor kinetics of multiple myeloma. (1973) (65)
- Role of gamma globulin for immunoprophylaxis in multiple myeloma. (1967) (63)
- Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. (1998) (61)
- Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. (1990) (58)
- Cellular kinetics in multiple myeloma. A new approach to staging and treatment. (1975) (57)
- Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy: A southwest oncology group study (1983) (56)
- Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma. (1967) (56)
- In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers (1997) (55)
- Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. (1990) (54)
- Long-term engraftment of fresh human myeloma cells in SCID mice. (1992) (53)
- Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study. (1998) (51)
- DOXORUBICIN/B.C.N.U. CHEMOTHERAPY FOR MULTIPLE MYELOMA IN RELAPSE (1976) (51)
- A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors (2001) (49)
- Effects of suramin on in vitro growth of fresh human tumors. (1992) (47)
- Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms (1990) (45)
- Tumor growth stimulation in vitro by interferons. (1983) (39)
- Relevance of multidrug resistance to rheumatoid arthritis: development of a new therapeutic hypothesis. (1996) (36)
- Evaluation of race as a prognostic factor in multiple myeloma. An ancillary of Southwest Oncology Group Study 8229. (1996) (34)
- Effects of tumor necrosis factor on sensitive and multidrug resistant human leukemia and myeloma cell lines. (1989) (33)
- Combination chemotherapy for advanced breast cancer utilizing vincristine, adriamycin, and cyclophosphamide (VAC) (1979) (33)
- The current status and future prospects of treatment for multiple myeloma. (1982) (32)
- Comparative trial of low‐dose adriamycin plus cyclophosphamide with or without additive hormonal therapy in advanced breast cancer (1979) (30)
- A phase I/II trial of paclitaxel for non‐Hodgkin's lymphoma followed by paclitaxel plus quinine in drug‐resistant disease (1998) (28)
- Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics. (1977) (27)
- The nature of cells generating human myeloma colonies in vitro (1979) (25)
- Serum can inhibit reversal of multidrug resistance by chemosensitisers. (1996) (25)
- “PARANEOPLASTIC” SYNDROMES ASSOCIATED WITH MONOCLONAL LYMPHOCYTE AND PLASMA CELL PROLIFERATION * (1974) (24)
- The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma. (1999) (23)
- Drug resistance in myeloma: mechanisms and approaches to circumvention. (1992) (22)
- In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein-associated Taxol resistance. (1993) (22)
- SPONTANEOUS EVOLUTION OF IMMUNE COMPETENCE IN DIGEORGE SYNDROME (1974) (21)
- Hemopoietic stem cell transplants for multiple myeloma. (1994) (19)
- Cellular kinetics staging, and immunoglobulin synthesis in multiple myeloma. (1975) (18)
- Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide) (2004) (18)
- Nitrosoureas in multiple myeloma. (1976) (16)
- Transplants for multiple myeloma (1995) (16)
- Immunoquantitation of free light chain immunoglobulins: applications in multiple myeloma. (1978) (16)
- Synthesis and Metabolism of Bence Jones Protein and Calculation of Tumour Burden in Patients with Bence Jones Myeloma (1981) (14)
- Phase II investigation of pentostatin in multiple myeloma: a Southwest Oncology Group study. (1990) (13)
- alpha-Interferon for remission maintenance: preliminary report on the Southwest Oncology Group Study. (1991) (12)
- Discrimination between human T and B lymphocytes by computer analysis of digitized data from scanning microphotometry. II. Discrimination and automated classification. (1978) (11)
- Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study. (1990) (11)
- Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. (1984) (10)
- Phase II study of Fludarabine Phosphate in multiple myeloma (1990) (9)
- Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues (1997) (8)
- Clinical staging and new therapeutic approaches in multiple myeloma. (1978) (8)
- Efficacy of prednisone in refractory multiple myeloma and measurement of glucocorticoid receptors (2004) (7)
- Therapeutic strategies in multiple myeloma. (1980) (6)
- Cell kinetic analysis of human tumor stem cells. (1980) (6)
- Prognostic correlation of plasma cell acid phosphatase and beta-glucuronidase in multiple myeloma: a Southwest Oncology Group study. (1991) (6)
- Discrimination between human T and B lymphocytes and monocytes by computer analysis of digitized data from scanning microphotometry. I. Chromatin distribution patterns. (1978) (5)
- Current concepts in the therapy of multiple myeloma. (1966) (5)
- Phase II trial of 4′-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer (2004) (4)
- IMMUNOLOGICAL RECONSTITUTION IN SEVERE COMBINED IMMUNODEFICIENCY DISEASE WITH TRANSPLANTATION FROM A NON-COMPATIBLE DONOR (1974) (4)
- Schedule dependent synergism of vinblastine (VLB) and cloned leukocyte interferon A (IFL-rA) (1981) (4)
- Cytotoxicity of mitomycin C on clonogenic human carcinoma cells is not enhanced by hypoxia (2004) (3)
- Increased peripheral blood leukocyte cytotoxic activity in cancer patients during the continuous intravenous administration of recombinant human tumor necrosis factor (2004) (3)
- Drug resistance in multiple myeloma associated with high in vitro incorporation of 3H-thymidine. (1981) (2)
- Effect of leukocyte interferons on cell proliferation of human tumors in vitro. (1984) (2)
- Aclacinomycin A in the treatment of multiple myeloma: A Southwest Oncology Group study (1990) (2)
- In vitro cytotoxicity against fresh human tumors and P388 leukemia predicts the differential in vivo activity of a series of anthracene anticancer drugs (1991) (2)
- A-phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma. A Southwest Oncology Group study. (1990) (2)
- Interferons in the treatment of multiple myeloma. (1990) (2)
- Cytostatic and cytotoxic activity of lymphokine-activated killer cell supernatants (2005) (1)
- Evaluation and Treatment of Multiple Myeloma and Related Disorders1 (1975) (1)
- Role of sequential fractionated hemibody irradiation as consolidation folloowing induction chemotherapy for previously untreated patients with multiple myeloma (1987) (1)
- A phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma (2004) (1)
- Alternating Combination Chemotherapy and Levamisole Improves Survival in Multiple Myeloma (2016) (1)
- Reversal of multidrug resistance in hematologic malignancies with chemosensitizers: laboratory and clinical studies (1994) (0)
- Comparison of assays used for in vitro chemosensitivity testing of human tumours. (1984) (0)
- New Therapeutic Approaches to Myeloma (2004) (0)
- multiple myeloma patients Maintenance therapy with alternate-day prednisone improves survival in (2013) (0)
- for Previously Untreated Multiple Myeloma Superiority of Tandem Autologous Transplantation Over Standard Therapy (2013) (0)
- A Phase II Evaluation of Esorubicin in Ovarian Cancer: A Southwest Oncology Group Study (1992) (0)
- Development of chemosensitizers (CS) for clinical reversal of P-glycoprotein (P-gp)-mediated multidrug resistance (MDR): 163 (1994) (0)
- Gene expression profiles associated with MDR1 expression in a doxorubicin-resistant human multiple myeloma cell line (1999) (0)
- MULTIDRUG RESISTANCE IN RHEUMATOID ARTHRITIS. AUTHORS' REPLY (1996) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Sydney E. Salmon?
Sydney E. Salmon is affiliated with the following schools:
